Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary Tumors.

Pituitary Tumors Clinical Trial

Official title:
Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary

Status Recruiting

Clinical Trial Summary

DNA methylation is one of the important ways of protein post-translational modification.Pituitary adenoma (PA) is a benign neuroendocrine tumor that originates from adenohypophysial 45 cells, and accounts for 10%-20% of all primary intracranial tumors. However some PAs can present with high invasiveness and irregular growth, which tend to compresses the optic chiasm and third ventricle, encase the internal carotid artery, and affect hormone secretion from the pituitary gland and hypothalamus. In this study we focus on the mechanism of DNA methylation on the invasiveness of pituitary tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05634655
Study type	Observational
Source	Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact	Wu Qun
Phone	13605810393
Email	2192010@zju.edu.cn
Status	Recruiting
Phase
Start date	January 1, 2022
Completion date	January 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01903967` - Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)	N/A
Completed	`NCT01689727` - Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors	Phase 2
Completed	`NCT01322945` - Barrow Nasal Inventory Survey	N/A
Completed	`NCT00565903` - Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Active, not recruiting	`NCT01794793` - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies	Phase 4
Completed	`NCT00462475` - Effect of 5 Years of GH Replacement on Atherosclerosis	Phase 4